Literature DB >> 22482740

[Refractory subacute cutaneous lupus erythematosus treated with rituximab].

D E Cieza-Díaz, J A Avilés-Izquierdo, C Ceballos-Rodríguez, R Suárez-Fernández.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22482740     DOI： 10.1016/j.ad.2011.10.013

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN： 0001-7310


× No keyword cloud information.
  5 in total

Review 1.  Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.

Authors:  Joshua Chang; Victoria P Werth
Journal:  Expert Rev Clin Immunol       Date:  2016-06-01       Impact factor: 4.473

Review 2.  Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology.

Authors:  Lyubomir A Dourmishev; Dimitrina V Guleva; Ljubka G Miteva
Journal:  Wien Med Wochenschr       Date:  2017-09-01

3.  Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.

Authors:  R R Winkelmann; Grace K Kim; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2013-01

4.  Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus.

Authors:  Mariana Álvares Penha; Ricardo da Silva Libório; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2018-06       Impact factor: 1.896

Review 5.  Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature.

Authors:  S C Hofmann; M J Leandro; S D Morris; D A Isenberg
Journal:  Lupus       Date:  2013-08       Impact factor: 2.911
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.